Immune checkpoint inhibitors: A breakthrough for immunotherapy

Immune checkpoint inhibitors (ICIs) have shown their efficacy, not only as a standalone treatment, but also when combined with traditional methods like chemotherapy and radiation. However, persistent challenges such as high costs and regulatory hurdles still exist. Gain expert knowledge on this novel approach to cancer therapy, with key topics including:

Clinical trial landscape in 2023
SWOT analysis of ICIs
Challenges around high costs and toxicity
Future trends, including the potential of PD-1 inhibitors

Sign up to our content service and access now

Your company email address

Please select your industry: (max 1)
Would you like to hear more from a Novotech expert about clinical trials?

Opt In?

By you requesting this resource, you agree to our terms of use. All data is protected by our Privacy Notice. You can change your contact preferences here. If you have any further questions please get in contact.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow Novotech to store and process the information submitted to provide you the content requested. They are subject to Novotech’s Terms and Conditions.

Immune checkpoint inhibitors: A breakthrough for immunotherapy

Sign up to our content service and access now

Opt In?

Explore similar content

Resiliency and innovation - Navigating the current biotech landscape

HIV – Global Clinical Trial Landscape

Incorporating Digital Biomarkers & Endpoints Into Clinical Trials: Key Regulatory Considerations